메뉴 건너뛰기




Volumn 119, Issue 16, 2013, Pages 2999-3006

Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria

(20)  Kroeger, Nils a,b   Xie, Wanling c   Lee, Jae Lyn d   Bjarnason, Georg A e   Knox, Jennifer J f   MacKenzie, Mary J g   Wood, Lori h   Srinivas, Sandy i   Vaishamayan, Ulka N j   Rha, Sun Young k   Pal, Sumanta K l   Yuasa, Takeshi m   Donskov, Frede n   Agarwal, Neeraj o   Kollmannsberger, Christian K p   Tan, Min Han q   North, Scott A r   Rini, Brian I s   Choueiri, Toni K c,t,u   Heng, Daniel Y C a  


Author keywords

Heng risk criteria; IMDC risk model; non clear cell renal cell carcinoma; overall survival; prognostication; targeted therapies

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; HEMOGLOBIN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TIVOZANIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

EID: 84881480218     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28151     Document Type: Article
Times cited : (199)

References (29)
  • 3
    • 51049084870 scopus 로고    scopus 로고
    • Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors
    • et al.
    • Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008; 14: 4726-4734.
    • (2008) Clin Cancer Res. , vol.14 , pp. 4726-4734
    • Nickerson, M.L.1    Jaeger, E.2    Shi, Y.3
  • 4
    • 80052263465 scopus 로고    scopus 로고
    • ICUD-EAU International Consultation on Kidney Cancer 2010: Treatment of metastatic disease
    • et al.
    • Patard JJ, Pignot G, Escudier B, et al. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol. 2011; 60: 684-690.
    • (2011) Eur Urol. , vol.60 , pp. 684-690
    • Patard, J.J.1    Pignot, G.2    Escudier, B.3
  • 5
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • et al.
    • Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356: 125-134.
    • (2007) N Engl J Med. , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 6
    • 64049084146 scopus 로고    scopus 로고
    • Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis
    • et al.
    • Escudier BJ, Ravaud A, Negrier S, et al. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. ASCO Meeting Abstracts. 2008; 26: 5025.
    • (2008) ASCO Meeting Abstracts. , vol.26 , pp. 5025
    • Escudier, B.J.1    Ravaud, A.2    Negrier, S.3
  • 7
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • et al.
    • Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356: 2271-2281.
    • (2007) N Engl J Med. , vol.356 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3
  • 8
    • 77956227464 scopus 로고    scopus 로고
    • Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors
    • et al.
    • Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010; 116: 4256-4265.
    • (2010) Cancer. , vol.116 , pp. 4256-4265
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 9
    • 68949145218 scopus 로고    scopus 로고
    • Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma
    • et al.
    • Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009; 27: 3584-3590.
    • (2009) J Clin Oncol. , vol.27 , pp. 3584-3590
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 10
    • 82755183572 scopus 로고    scopus 로고
    • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial
    • et al.
    • Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011; 378: 1931-1939.
    • (2011) Lancet. , vol.378 , pp. 1931-1939
    • Rini, B.I.1    Escudier, B.2    Tomczak, P.3
  • 11
    • 73349084973 scopus 로고    scopus 로고
    • Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study
    • et al.
    • Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009; 27: 5794-5799.
    • (2009) J Clin Oncol. , vol.27 , pp. 5794-5799
    • Heng, D.Y.1    Xie, W.2    Regan, M.M.3
  • 12
    • 84873080330 scopus 로고    scopus 로고
    • External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: A population-based study
    • et al.
    • Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol. 2013; 14: 141-148.
    • (2013) Lancet Oncol. , vol.14 , pp. 141-148
    • Heng, D.Y.1    Xie, W.2    Regan, M.M.3
  • 13
    • 3242770671 scopus 로고    scopus 로고
    • Overall C as a measure of discrimination in survival analysis: Model specific population value and confidence interval estimation
    • Pencina MJ, D'Agostino RB,. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med. 2004; 23: 2109-2123.
    • (2004) Stat Med. , vol.23 , pp. 2109-2123
    • Pencina, M.J.1    D'Agostino, R.B.2
  • 14
    • 77952318310 scopus 로고    scopus 로고
    • Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206
    • et al.
    • Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010; 28: 2137-2143.
    • (2010) J Clin Oncol. , vol.28 , pp. 2137-2143
    • Rini, B.I.1    Halabi, S.2    Rosenberg, J.E.3
  • 15
    • 18844386435 scopus 로고    scopus 로고
    • Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy
    • Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB,. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother. 2005; 28: 488-495.
    • (2005) J Immunother. , vol.28 , pp. 488-495
    • Upton, M.P.1    Parker, R.A.2    Youmans, A.3    McDermott, D.F.4    Atkins, M.B.5
  • 16
    • 0036569472 scopus 로고    scopus 로고
    • Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology
    • Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V,. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology. J Clin Oncol. 2002; 20: 2376-2381.
    • (2002) J Clin Oncol. , vol.20 , pp. 2376-2381
    • Motzer, R.J.1    Bacik, J.2    Mariani, T.3    Russo, P.4    Mazumdar, M.5    Reuter, V.6
  • 17
    • 37849001813 scopus 로고    scopus 로고
    • Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
    • et al.
    • Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008; 26: 127-131.
    • (2008) J Clin Oncol. , vol.26 , pp. 127-131
    • Choueiri, T.K.1    Plantade, A.2    Elson, P.3
  • 18
    • 67651201656 scopus 로고    scopus 로고
    • Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial
    • et al.
    • Gore ME, Szczylik C, Porta C, et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 2009; 10: 757-763.
    • (2009) Lancet Oncol. , vol.10 , pp. 757-763
    • Gore, M.E.1    Szczylik, C.2    Porta, C.3
  • 19
    • 84864922628 scopus 로고    scopus 로고
    • Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma
    • et al.
    • Lee JL, Ahn JH, Lim HY, et al. Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Ann Oncol. 2012; 23: 2108-2114.
    • (2012) Ann Oncol. , vol.23 , pp. 2108-2114
    • Lee, J.L.1    Ahn, J.H.2    Lim, H.Y.3
  • 20
    • 84868532639 scopus 로고    scopus 로고
    • A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma
    • et al.
    • Tannir NM, Plimack E, Ng C, et al. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012; 62: 1013-1019.
    • (2012) Eur Urol. , vol.62 , pp. 1013-1019
    • Tannir, N.M.1    Plimack, E.2    Ng, C.3
  • 21
    • 84875614863 scopus 로고    scopus 로고
    • Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma
    • et al.
    • Koh Y, Lim HY, Ahn JH, et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol. 2013; 24: 1026-1031.
    • (2013) Ann Oncol. , vol.24 , pp. 1026-1031
    • Koh, Y.1    Lim, H.Y.2    Ahn, J.H.3
  • 22
    • 67651056360 scopus 로고    scopus 로고
    • Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies
    • et al.
    • Dutcher JP, de Souza P, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009; 26: 202-209.
    • (2009) Med Oncol. , vol.26 , pp. 202-209
    • Dutcher, J.P.1    De Souza, P.2    McDermott, D.3
  • 23
    • 34547108341 scopus 로고    scopus 로고
    • Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy
    • et al.
    • Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer. 2007; 110: 543-550.
    • (2007) Cancer. , vol.110 , pp. 543-550
    • Choueiri, T.K.1    Garcia, J.A.2    Elson, P.3
  • 24
    • 80051699497 scopus 로고    scopus 로고
    • Prognostic model for survival in patients with metastatic renal cell carcinoma: Results from the international kidney cancer working group
    • et al.
    • Manola J, Royston P, Elson P, et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res. 2011; 17: 5443-5450.
    • (2011) Clin Cancer Res. , vol.17 , pp. 5443-5450
    • Manola, J.1    Royston, P.2    Elson, P.3
  • 25
    • 54049095545 scopus 로고    scopus 로고
    • Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
    • et al.
    • Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2008; 113: 1552-1558.
    • (2008) Cancer. , vol.113 , pp. 1552-1558
    • Motzer, R.J.1    Bukowski, R.M.2    Figlin, R.A.3
  • 26
    • 33750293584 scopus 로고    scopus 로고
    • Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling
    • et al.
    • Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A. 2006; 103: 15552-15557.
    • (2006) Proc Natl Acad Sci U S A. , vol.103 , pp. 15552-15557
    • Baba, M.1    Hong, S.B.2    Sharma, N.3
  • 27
    • 79960378039 scopus 로고    scopus 로고
    • New insights into the biology of renal cell carcinoma
    • Li L, Kaelin WG Jr,. New insights into the biology of renal cell carcinoma. Hematol Oncol Clin North Am. 2011; 25: 667-686.
    • (2011) Hematol Oncol Clin North Am. , vol.25 , pp. 667-686
    • Li, L.1    Kaelin, Jr.W.G.2
  • 28
    • 84872548337 scopus 로고    scopus 로고
    • Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
    • et al.
    • Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013; 31: 181-186.
    • (2013) J Clin Oncol. , vol.31 , pp. 181-186
    • Choueiri, T.K.1    Vaishampayan, U.2    Rosenberg, J.E.3
  • 29
    • 0036138580 scopus 로고    scopus 로고
    • Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
    • Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M,. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002; 20: 289-296.
    • (2002) J Clin Oncol. , vol.20 , pp. 289-296
    • Motzer, R.J.1    Bacik, J.2    Murphy, B.A.3    Russo, P.4    Mazumdar, M.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.